COVID-19: Glenmark launches Coronavirus drug at ₹103 per tablet in India

On Saturday, Glenmark Pharmaceuticals launched antiviral drug Favipiravir under the name of FabiFlu, for mild to moderate Coronavirus patients. This drug is available as a 200mg tablet and will cost ₹ 103 per tablet which means ₹ 3,500 for s strip of 34 tablets. According to the drug firm, FabiFlu is the first oral favipiravir prescription based medicine. The recommended dose is 1,800 mg twice daily on day one and 800mg twice daily up to day 14.

“Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the 1st month itself. We will be closely monitoring the evolving situation and basis the situation, we will work to scale and meet the healthcare needs of the country,” said Glenmark answering manufacturing capacity questions.

Answering whether the company is looking for tie-ups with hospitals for drug supply, Glenmark said, “Our effort right now is to prioritise manufacturing to ensure FabiFlu is accessible to all patients who need it. Glenmark will certainly make a consideration to support private and public healthcare facilities and arrange for other suitable options as per the need and in time.”

FabiFlu got the approval from Drugs Controller General of India on Friday. Glenn Saldanha, Chairman and Managing Director at Glenmark Pharmaceuticals said, “This approval comes at a time when cases in India are spiralling like never before, putting tremendous pressure on our healthcare system.”

Sujesh Vasudevan, President at Glenmark Pharmaceuticals India said “We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for Covid-19… It has a wide therapeutic safety margin for Covid-19 at the dose that we administer.”

This medicine can be used for treatment only after the patient has signed informed consent.
This oral product could help especially when the health infrastructure is strained. It can also be used by patients with co-morbid conditions like diabetes and heart diseases with moderate Coronavirus symptoms. This drug provides faster symptomatic and radiological improvement.